Lilly to acquire California-based biopharma company in $1.2B deal

Please subscribe to IBJ to decode this article.

bd qcina.ioxeent hi a Ld dihaeafgee sra rt-aiiDeltdenvn2eddoi b-cn llB snr n aI eslCr nsngaynocu sd.lolstdn lcceoaadeudumaa. as i oSgled $ineaaaa1l ,ii npoaabroyaC-srarliiuEViecdenhWnnaoueneyek ml

ne-1i-/i_n f neme"tactwi-eess-icenwWeihoa yulkmsJyojx imloor=T thitn njme/tyaacuea-etws

h tB oserihbmdiniaieysagyntwksictyaosoprcrn soitceipuaplunrnc, tfacenieVenlamkaryo"pstxaldssp> fe o rniftt Lhhey ovsdoviecrlReol

fepsve iesiiac auttrSthaasdcds it snogn-mfhyxaiarsd ukasfnfrsietw'i"ed>ossc"ssssoeseiittuobeyr ncgirort atgrei s dadenselrv aearaenknsclnaerasyaecrlabioelmlcaag rdsia. nna ai nhsn cvnsod"miaorabd ceoac ,oheoe eyettb anotutVtaiydcdal uon etmo estng akgi ndiumltepriim eislg

hs iceh spnfusatloiyaysmnmoMeeRa=somkmn-auout,Cac aaedp aotmotainhhnaznos lc a era-sOcxaripdjsjiniahutL' ies cersr"dPtt>gsaiN/dena ofhraopact.oibeaanllme"ceBrkcm-3roi"eiMgodn driRo vitd aentt ctEn aaarroe e io emoibo

g,hesx e1n vte ca i$2L oindr lftphV ettreiads 'yn6eqpqaotstis ft3e mo2eon, t otexmsit iga0 aewa1 a d rhwaoe e oafy on l,nacd$n nenlaehautlpeolsiyuaci hii bne ns rle ok c-codooeoa .cg snsaur.hi caeac oeslTltngen 4,aytfl ihmoa no ramt rymril jngtair u raem.n g ipd seiygrt c lsaye,meddwun nh%ehtibec rahpeuvtiwclUt pir

tu n octdali otyarv so tgntV edf i gnss ieses prlad esrc npfxeolhanid.ecrfoengsgr,iewconAaot dnrm v araeeee

dvagoonrdsergot pLeoav/edtto ofi,aloil lac rinmivdsri>opc ebdadtre e Mtthth tamntpir

t h b tdoiyts causve ftclkdnTctih hdoxan has y tVtehw cr e,aphe bis seefohxseerllyif e .os t cpepil r ietsrlaoojo,